The agreements will cover two years with an expected volume of 325 tons per month to generate around €300,000 per year in expected revenues.

The exclusive licence will see the strain’s inclusion into dietary supplements formulation available to customers in the United States and Canada.

The PISCES II phase 2a clinical trial was an open-label study in patients living with significant disability resulting from ischaemic stroke.

“We are extremely pleased to address another market with our first oncology test which has already seen traction in the UK and Europe since its launch in September 2019, and reinforces our strategic plans of product penetration and geographic expansion,” said Lyn Rees, Chief Executive of Yourgene.

The group has said it believes the deal will strengthen the company’s presence in the East Midlands in line with its strategy to accelerate organic growth through acquisitions which are considered a ‘cultural fit.’

The European-focused resource company said the study had identified the cut and fill method, as opposed to sub-level stoping, as the proffered method for the mining model.

Steve Brown, CEO of accesso commented, “These contract wins and renewals reaffirm the strength of our product offerings, underscore the confidence our customers have in our solutions, and start us off with forward momentum in 2020.”

The pharmaceutical company told investors that it intends to approve its erectile dysfunction (ED) gel product, which utilises the DermaSys® technology, as a medical device rather than a drug.

Having made an underlying loss of £1.2mn in 2019, the group said it expects to report positive adjusted EBITDA for FY20 compared to finnCap’s forecasted £0.2m loss.

“Leo has worked with Open Orphan for the past year and is therefore well placed to assist with the rapid integration of hVIVO, deliver on our synergies programme and target profitability in the near term,” said Cathal Friel, Executive Chairman of Open Orphan.